このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Ambient AI Clinical Trial

2026年5月22日 更新者：Chris Lewis、University of Washington

Evaluation of Abridge Ambient AI Technology Regarding Provider Burnout and Patient Satisfaction With the Clinical Encounter

This is a single-site pragmatic randomized control trial studying the effect of ambient artificial intelligence (AI) scribes on the delivery of medical care to patients in the ambulatory setting. The study will last 150 days and include up to 65 providers in the intervention group. Providers will be recruited from three medical specialties, including primary care, oncology, and urology. The study will enroll providers and randomize them to an intervention group (access to the ambient AI scribe product) or a control group (routine patient care). Providers will be evaluated for burnout and task load measures through digital surveys at the beginning, middle, and end of the study. Provider electronic health record (EHR) usage data will also be evaluated for time spent documenting, time spent after hours on days with scheduled clinical care, and time between the start of the clinical encounter and signing it.

調査の概要

状態

完了

条件

介入・治療

研究の種類

介入

入学 (実際)

139

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

  • アメリカ
    • Washington
      • Seattle、Washington、アメリカ、98195
        • University of Washington Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Provider is an employee of the University of Washington Medicine.
  • Clinical specialty of primary care, oncology, or urology.
  • Clinical full-time equivalent (FTE) of 0.2 or greater (provider must have an outpatient clinic of at least 20% of an FTE).
  • Provider is a physician or an advanced practice provider.

Exclusion Criteria:

  • Trainees (e.g., medical students, residents, or fellows)
  • Provider does not have access to a mobile device that is compatible with the ambient AI scribe service (e.g., Android mobile phone).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：ヘルスサービス研究
  • 割り当て：ランダム化
  • 介入モデル：並列代入
  • マスキング：なし（オープンラベル）

武器と介入

参加者グループ / アーム
介入・治療
実験的：Ambient AI scribe users
Participants in this arm will utilize the ambient AI scribe tools from Abridge. They will otherwise continue their usual clinical activities, including providing care with trainees (e.g., medical students, residents) and multiple family members in the room. The tool will be used exclusively in the outpatient clinical setting and only when the participant is present. The ambient AI scribe tool integrates into the electronic health record (EHR), and the EHR's mobile app is used to collect the recording on a mobile device. The ambient AI scribe tool is transcriptional and does not provide clinical decision support.
他の：Use of Ambient AI scribe tool on participant's mobile device

Ambient artificial intelligence (AI) scribes are a clinical documentation tool that uses automated speech recognition and large-scale language models to capture and transcribe synchronous patient-provider encounters in real time. Clinicians then review, edit, and authorize the AI-generated text before finalizing the chart, ensuring necessary human oversight and medical accuracy. In this study, participants used Ambient AI scribes on mobile devices for the recordings.

The ambient AI scribe will be available for the provider to use in the outpatient setting. They were not required to use the Ambient AI scribe, but could choose whether to use it and with which patients. Consent to use the device was documented for all patient encounters.

他の名前：
  • アブリッジ
介入なし：Routine patient care (no AI scribe)
These participants were not provided with the ambient AI scribe application on their mobile device. They still had access to documentation with dictation or existing scribe services (non-AI).

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Professional Fulfillment Index (PFI)
時間枠：Surveyed at enrollment (day 0 of pilot), midpoint (day 75), and end of pilot (day 150)
Change in professional fulfillment and burnout, measured using the Professional Fulfillment Index (PFI), a validated 16-item self-report questionnaire. The instrument comprises three subscales: Professional Fulfillment (6 items), Work Exhaustion (4 items), and Interpersonal Disengagement (6 items). Items are rated on a 5-point Likert scale (0 = "Not at all true" / "Not at all" to 4 = "Completely true" / "Extremely"). Subscale scores are calculated as the mean of constituent items. Unit of measure: mean subscale score (range 0-4) and overall burnout score (mean of Work Exhaustion and Interpersonal Disengagement subscales, range 0-4).
Surveyed at enrollment (day 0 of pilot), midpoint (day 75), and end of pilot (day 150)
Mean Score on NASA Task Load Index (NASA-TLX)
時間枠：Surveyed at enrollment (day 0 of pilot), midpoint (day 75), and end of pilot (day 150)
Change in perceived workload, measured using the NASA Task Load Index (NASA-TLX), a validated multidimensional self-report questionnaire. The instrument comprises six subscales: Mental Demand, Physical Demand, Temporal Demand, Performance, Effort, and Frustration. Each subscale is rated on a 0-100 scale in 5-point increments. Unit of measure: subscale score (range 0-100) and overall workload score, calculated as the unweighted mean of the six subscales (range 0-100). Higher scores indicate greater perceived task workload associated with clinical documentation.
Surveyed at enrollment (day 0 of pilot), midpoint (day 75), and end of pilot (day 150)
Ambient AI scribe utilization rate (%)
時間枠：Through study completion, up to 150 days after the start of the pilot.
Percentage of clinical encounters in which the provider used the Abridge ambient AI scribe, measured using Abridge platform usage logs cross-referenced with electronic health record (EHR) encounter data. Unit of measure: utilization rate, calculated as (number of encounters in which Abridge was used divided by the total number of clinical encounters during the same period). This fraction is then represented as a percentage (range 0-100%) and aggregated monthly by provider.
Through study completion, up to 150 days after the start of the pilot.

二次結果の測定

結果測定
メジャーの説明
時間枠
Time Spent in the Electronic Health Record on Clinical Note Documentation (Minutes)
時間枠：Through study completion, up to 150 days after the start of the pilot.
Time spent by the provider in the electronic health record on clinical note documentation activities, measured using EHR audit log data (e.g., Epic Signal Provider Efficiency Profile). Unit of measure: minutes per scheduled clinic day on note documentation, normalized to clinical workload (clinical Full-Time Equivalent), and aggregated in 4-week windows per provider. No patient information will be collected for this outcome measure.
Through study completion, up to 150 days after the start of the pilot.
Time spent in the electronic health record outside of working hours
時間枠：Through study completion, up to 150 days after the start of the pilot.
Time spent by the provider in the electronic health record outside of scheduled clinic/working hours (commonly referred to as "work outside of work" or "pajama time"), measured using EHR audit log data (e.g., Epic Signal Provider Efficiency Profile). Unit of measure: minutes per scheduled clinic day spent in the EHR outside of working hours, normalized to clinical workload and aggregated in 4-week windows per provider. No patient information will be collected for this outcome measure.
Through study completion, up to 150 days after the start of the pilot.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

University of Washington

捜査官

  • 主任研究者：Christopher W Lewis, MD, MS、University of Washington

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年12月19日

一次修了 (実際)

2025年7月4日

研究の完了 (実際)

2025年7月4日

試験登録日

最初に提出

2026年4月27日

QC基準を満たした最初の提出物

2026年5月13日

最初の投稿 (実際)

2026年5月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月28日

QC基準を満たした最後の更新が送信されました

2026年5月22日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • STUDY00022081

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All participant data will be deidentified (limited dataset), aggregated, or normalized. Data will be managed and stored on Dryad (https://datadryad.org/), a nonprofit membership organization that is committed to making data available for research and educational reuse.

IPD 共有時間枠

Data will be available for at least 10 years.

IPD 共有アクセス基準

Data will be shared with qualified researchers whose proposed use has been approved by an institutional review board. Request for deidentified data will be available through Dryad. Requests for additional data can be made to the study's PI.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する